ERBB2 and breast carcinoma: Because the TNBC subtypes do not express the three receptors, there are limitations to therapies such as trastuzumab and pertuzumab (; targeting HER2) or tamoxifen (; targeting ER), which are commonly used in breast cancer [5, 6].